SCHEMBL1605121

SCHEMBL1605121

FC(F)(F)[s+]1c2ccccc2c2ccccc21

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29483958 1.00 ALDH1A1 (0.32) ALDH1A1TSHR
SCHEMBL6995721 0.93
SCHEMBL30800272 0.93 ACHE (0.31)
SCHEMBL629520 0.93 ACHE (0.31)
Trifluoromethanesulfonic Acid SCHEMBL115549 0.84 GPR3 (0.44)
Trifluoromethanesulfonic Acid SCHEMBL7978113 0.84 PTPN1 (0.33) TSHR
Trifluoromethanesulfonic Acid SCHEMBL29483957 0.84 GPR3 (0.44)
SCHEMBL6757022 0.80 KIF11 (0.31)
SCHEMBL356010 0.78 LMNA (0.33)
SCHEMBL5690738 0.75 MAPK1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371422-B2 Fluorine-containing pyrimidine compound and manufacturing method for same UNIMATEC CO., LTD. (JP) 2025-07-29 US disclosed
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-04-24 US disclosed
US-20250019579-A1 COMPOSITION BASED ON (METH)ACRYLATE MONOMERS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2025-01-16 US disclosed
EP-4437056-A1 COMPOSITION BASED ON (METH)ACRYLATE MONOMERS Bostik SA (FR) 2024-10-02 EP disclosed
US-20240150329-A1 FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR SAME UNIMATEC CO., LTD. (JP) 2024-05-09 US disclosed
EP-4308616-A1 COMPOSITION BASED ON (METH)ACRYLATE MONOMERS Bostik SA (FR) 2024-01-24 EP disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
WO-2023089252-A1 COMPOSITION BASED ON (METH)ACRYLATE MONOMERS BOSTIK SA (FR) 2023-05-25 WO disclosed
US-20230159502-A1 INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2022195221-A1 COMPOSITION BASED ON (METH)ACRYLATE MONOMERS BOSTIK SA (FR) 2022-09-22 WO disclosed
US-20070049651-A1 Curable composition, ink composition, inkjet recording method, printed material, method of producing planographic printing plate, planographic printing plate, and oxcetane compound FUJI PHOTO FILM CO., LTD. 2007-03-01 US disclosed
EP-1753736-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 Amgen Inc. (US) 2007-02-21 EP disclosed
US-20070003871-A1 Positive photosensitive composition FUJI PHOTO FILM CO., LTD. 2007-01-04 US disclosed
EP-1419155-B1 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2006-11-08 EP disclosed
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2006-06-29 US disclosed
WO-2005116002-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2005-12-08 WO disclosed
EP-1419155-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2004-05-19 EP disclosed
WO-2003010138-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-02-06 WO disclosed
US-6239289-B1 PERFLUOROALKYLATING A NUCLEOPHILE; STABILITY DAIKIN INDUSTRIES LTD. (JP) 2001-05-29 US disclosed
EP-1013651-A1 O-(PERFLUOROALKYL)DIBENZOFURANIUM SALT DERIVATIVES, INTERMEDIATES FOR THE PREPARATION OF THE SAME, PROCESS FOR THE PREPARATION OF THE INTERMEDIATES, PERFLUOROALKYLATING AGENTS, AND PROCESS FOR PERFLUOROALKYLATION Daikin Industries, Limited (JP) 2000-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159502-A1 INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 ALDH1A1 315/4885TSHR 1766/4885
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1B, SCN1A, SCN2B ALDH1A1 1828/4885TSHR 1204/4885
US-12371422-B2 Fluorine-containing pyrimidine compound and manufacturing method for same CNOT1, FXR1, CYP1B1 ALDH1A1 544/4885TSHR 2986/4885
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 ALDH1A1 100/4885TSHR 2428/4885
US-20240150329-A1 FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR SAME CNOT1, FXR1, CYP1B1 ALDH1A1 544/4885TSHR 2986/4885
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A ALDH1A1 2190/4885TSHR 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.